Peter Sandys is Chairman of Seroba. He was a co-founder of the firm, acting as Managing Partner until 2021 when he transitioned to the role of Chairman.
Peter has held many directorships in the fund management, technology and financial services industries. He was previously Managing Director of ABN Amro Corporate Finance (Ireland) Limited where he had responsibility for the firm’s capital markets and venture capital businesses. Prior to joining ABN Amro, Peter worked in Corporate Advisory Services for Ernst & Young (E&Y) in London and Dublin. During this period, Peter was also seconded to 3i venture capital. Prior to joining E&Y, he worked for KPMG.
Peter has a BBS degree from TCD and is a Chartered Accountant. He has served twice as Chairman of the Irish Venture Capital Association and was a member of the Irish Stock Exchange’s New Issues Committee and the committee of the Irish Bio Industries Association. He was also formerly a member of the Securities Institute, a Registered Stockbroker and a member of the Institute of Taxation in Ireland. Peter sits on the board of Quanta Dialysis Technologies and was previously on the board of PrecisionBiotics (acquired by Novozymes.)
Bruno Montanari is a Partner at Seroba. He has a background in venture capital and in investment banking, with a focus on the pharmaceutical, biotechnology and medical device industries.
Bruno graduated in 1998 with a PharmD. from the Université René Descartes, Paris V and in the same year completed a Master’s degree in Strategic Management at HEC.
Prior to joining the firm in 2017, Bruno was a Partner at Omnes Capital (Paris) in charge of life sciences investments for the venture capital team. His previous venture capital experience was at Atlas Venture (Paris/London) and CDP Capital (Paris/Montreal). He started his career in 1999 in London, in the healthcare teams of the investment banking divisions of Deutsche Bank and later Merrill Lynch. Bruno brings a wealth of experience and network, particularly in continental Europe, where he is based.
Bruno sits on the boards of Coave Therapeutics, STORM Therapeutics and Sibylla Biotech.
Jennifer McMahon is a Partner at Seroba. She graduated from UCD with an honours degree in Pharmacology in 2010. Jennifer then entered a Master’s degree programme in Biotechnology and Business to further her interest in the interface of biomedical science with commercialisation.
Having placed first in her Master’s degree in 2011, Jennifer then joined Seroba’s Investment Team as an Investment Analyst, progressing to Partner in 2022.
In 2019, Jennifer joined the Advisory Board for the European healthcare Businesswomen’s Association. She is Chair of Level20 Europe and was a founder member of the Ireland Chapter of Level20. She guest lectures on venture capital at University College Dublin, Trinity College Dublin and the Royal College of Surgeons in Ireland. She is also in high demand as a speaker at Investor/Entrepreneur life science partnering conferences across Europe.
Jennifer sits on the boards of Endotronix, Palliare and Deciphex, is a Board Observer to Shorla Pharma and was previously on the Board of Biosensia prior to its merger with Kypha Diagnostics.
Daniel O’Mahony is a Partner at Seroba and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation.
Daniel was involved in corporate venture at Elan Corporation from 1996-2003. He was an advisor and consultant to Kernel Capital venture capital fund from 2001 and a partner from 2008, focusing on investments in life sciences. He joined Seroba as partner in 2009.
Daniel graduated with a Ph.D. from the National University of Ireland, Cork in 1986 and holds a business degree in technology management from the Smurfit Business School, University College Dublin (2000). He has held academic appointments at the Genetics Department, Trinity College, Dublin, the Weis Research Centre, Geisinger Clinic, Pennsylvania, USA and the Department of Medicine & Experimental Therapeutics at University College Dublin. He has published in several scientific journals and is co-inventor on numerous patent families.
Dr O’Mahony currently sits on the boards of Atlantic Therapeutics and Perfuze. He previously sat on the boards of Apica Cardiovascular (acquired by Thoratec), Covagen (acquired by Cilag/Janssen Pharmaceutical Companies of the Johnson & Johnson Group), Medlumics, Stokes Bio (acquired by Life Technologies), Straatum (acquired by Lam Research Corporation), Novate Medical (acquired by BTG) and PQ Bypass (acquired by Endologix).
Partner, Investor Relations
Maud Lazare is a Partner with Seroba with responsibility for Investor Relations. She has a background in private equity and asset management.
Maud graduated from Université Pierre et Marie Curie, Paris VI, with a Masters in Fundamental Mathematics, as well as from Université Paris Dauphine with a Masters in Modelling, Optimisation, Decision and Organisation.
Prior to joining Seroba in 2023, Maud was a Partner with French life science VC, Truffle Capital, where she was responsible for Investor Relations. Her previous experience was at Massena Partners, a family-office where she also held a role at its Private Markets spin-off, Essling Capital. In addition, Maud has held business development roles in asset management firms such as La Française and Richelieu Finance. She began her career as an equity derivatives trader in BNP, based in both Paris and Tokyo.
Alan O’Connell is a Partner at Seroba. He has a background in product and business development in the pharmaceutical and biotechnology industries.
Prior to joining the firm in 2003, Alan worked in a variety of product and business development roles at Elan Corporation (Dublin), American Biogenetic Sciences, Inc. (New York), and he also spent time in the Pharmacovigilance section at the Medicines and Healthcare Products Regulatory Agency (London). His previous venture capital experience was gained at Estée Lauder Investments (New York) and he still sits on the scientific advisory board of the Lauder funded Alzheimer’s Drug Discovery Foundation.
Alan graduated with a Ph.D. (neuropharmacology) from the National University of Ireland, Galway in 1994 and has a Master’s degree in pharmacology from the University of London (1990). He carried out post-doctoral neuroscience research at University College, Dublin and has published in several scientific journals.
Alan sits on the boards of: Ario Pharma; Crescent Diagnostics and Shorla Pharma.
He previously sat on the boards of Fusion Pharmaceuticals (NASDAQ: FUSN), Prexton Therapeutics (acquired by Lundbeck), Veryan Medical (acquired by Otsuka Medical) and Xention (exited via pharma partnerships).
Partner & CFO
Andrew Duignan is a Partner and Chief Financial Officer of Seroba. He graduated from Dublin City University in 2005 with an honours degree in Accounting & Finance and became a qualified chartered accountant in 2010. Andrew is also a qualified tax consultant.
Prior to joining the Seroba team in 2011, Andrew worked as Financial Controller of Appleyard Motors. Previously, Andrew was a tax consultant in RSM Farrell Grant Sparks and he has also held positions with AIBBNY and Citco Fund Services.
Vicky La Touche-Price
Marketing & Operations
Vicky La Touche-Price joined the Seroba team in 2010. A graduate of University College Dublin, she studied for her post-graduate diploma in Marketing in Hemel Hempstead in the UK and she also holds a Digital Marketing diploma from the MII in Dublin.
Previously with McDonnell Douglas Aviation Corporation, Guinness Ireland and DHL Worldwide, Vicky has worked in various international marketing roles in Europe and across a number of Gulf States in the Middle East and in the Near East. Vicky is now based back in Ireland and is responsible for operations and marketing for Seroba Life Sciences.
Anita is an Accountant at Seroba. She is a Member of the Association of Chartered Certified Accountants (ACCA) since 2020 and holds a Bachelor of Science Degree from Rochester Institute of Technology, NY in the United States.
Prior to joining the Seroba team in January 2022, Anita worked as a Management Accountant for CFO Services. Previously, she worked as an Assistant Accountant for Comans Beverages ltd. and has also worked as an Income Auditor for Kempinski Hotels.
Dr Jeanne Bolger
Jeanne Bolger, MB BCh BAO, is a Venture Partner with Seroba.
Jeanne has over 35 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD) and Venture Investments. She spent 11 years in Licensing and Acquisition (L&A), including Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, and before that as Director in the Business Development group at GlaxoSmithKline.
Jeanne spent nearly 10 years (2012-2022) as Vice President Venture Investment in J&J’s corporate venture fund, Johnson & Johnson Innovation – JJDC. During that period, she was based in London, leading investments across Europe in start-up and early stage life science companies in areas of strategic interest to J&J’s business sectors in Pharmaceuticals and Biotechnology, Medical Devices and Consumer. She represented JJDC on the Board of Directors of over a dozen companies, including Aelix Therapeutics, Asceneuron SA, Aviado Bio, Biocartis, Calypso Biotech, Inivata, Merus, Pulmocide, S-Biomedic, Syndesi, T-Rex. Dr Bolger also represented JJDC’s LP investments in multiple Venture Capital Funds in UK and Europe as well as representing J&J’s interests in other funding vehicles including incubators and accelerators.
Jeanne received her medical degree from University College Dublin. She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine at Trinity College Dublin. Jeanne sits on the Industry Advisory Board of CURAM, the SFI-funded Centre of Excellence charged with designing the next generation of smart medical devices, and on the Advisory Group of the National Health Innovation Hub which focuses on digital innovation in healthcare. She is on the Advisory Board of the Sir Francis Crick Translational Fund (UK), Chair of Board of Directors at Exevir SA (Private, Belgium) and Non-executive Director at Life Healthcare Group Holdings (JSE:LHC).